Bortezomib is a reversible inhibitor of the chymotrypsin —like activity of the 26S proteasome in mammalian cells. Bortezomib is a novel synthetic dipeptide boronic acid with a high specificity for the 26S proteasome and a first-in-class proteasome inhibitor with antitumor activity. The consequence of inhibiting the proteasome is the matter of some speculation: the P27 protein is a critical regulator of the cell cycle, and the degradation of P27 is actually prevented by proteasome inhibition.


The recommended dose of MYLOSOME is 1.3 mg/m2 /dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12-21). For extended therapy of more than 8 cycles, MYLOSOME may be administered on the standard schedule or on a maintenance schedule of once weekly for 4 weeks (Days 1, 8, 15, and 22) followed by a 13-day rest period (Days 23 to 35). Atleast 72 hours should elapse between consecutive doses of MYLOSOME.


MYLOSOME (Bortezomib) for (Rapid bolus I.V.) injection is indicated for the treatment of Myeloma patients who have received at least 1 prior therapy.

Product Information

MYLOSOME Inj. 2 mg (Bortezomib) for Injection (Rapid bolus I.V.) is supplied as individually cartoned 10ml vials containing Bortezomib as a white to off-white cake or powder.


For the use of an Oncologist / a Hospital / a Cancer Institute